Clay Siegall was the founding partner of the Seattle Genetics back in the year 1998. Today, he is the organization’s Directors’ board member, President and also the Chief Executive Officer. The philosophy Doctor has been in the cancer research and therapeutic drug-making industry for about twenty years.
Through the help of Siegall, Seattle Genetics has accomplished significant goals in the development of a rich blend of clinical and pre-clinical individuals for cancer and autoimmune indications. It is the leading firm in the development of technologies related to antibodies such as the great anti-body conjugate platform. Siegall has successfully managed to spearhead the company’s activities in generating capital from public and private financial institutions. His ambitions to transform Seattle Genetics from the traditional drug development to the extensive marketing of its modern drugs internationally; thus making the company a dominant biotech firm all around the globe. The company has also secured significant strategic collaborations with Genentech, MedImmune, and Bayer among others that have led to the generation of more revenue for the company.
Before his debut at Seattle Genetics, Siegall was working at Bristol-Myers Squibb Pharmaceutical Research Institution in the position of the head research investigator. Consequently, he held the position of the senior scientist in this same organization. Besides, Siegall has worked for Ultragenyx Pharmaceutical, Inc. and the Alder Biopharmaceuticals during his career in pharmacy. Additionally, Clay Siegall holds the position of the Director of the Washington Biotechnology and the Biomedical Association alongside his services as a member of Governors’ board in Fred Hutchinson Cancer Research Business Alliance. Siegall also acted as a Director to Mirna Therapeutics Company.
Notably, besides his numerous career achievements, Clay Siegall has authored many scientific papers and an editorial board member to reputable science-related journals. He also owns about nine patent rights of operation. Cancer Research Treatment Foundation benefits from his contributions as a counselor in its scientific board. In 1995, Siegall received Pierce Award due to his significant contributions to the targeted toxins control field. Later in 2002, the healthcare icon was honored with an award as the year’s Ernst and Young Entrepreneur finalist in Pacific Northwest.
Clay Siegall owes his scientific contributions to the medical career to a good education base. He attained his Ph.D. in Genetics from the George Washington University. Moreover, he graduated from the University of Maryland with a Bachelors of Science in Zoology. As such, Seattle Genetics has a v v great future growth and development opportunity in the hands of Clay Siegall.